AustralianSuper Pty Ltd Has $43.73 Million Holdings in Edwards Lifesciences Corporation $EW

AustralianSuper Pty Ltd lessened its stake in Edwards Lifesciences Corporation (NYSE:EW) by 63.8% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 559,115 shares of the medical research company’s stock after selling 984,313 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Edwards Lifesciences were worth $43,728,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in EW. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $266,000. Perigon Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 6.9% in the first quarter. Perigon Wealth Management LLC now owns 4,325 shares of the medical research company’s stock valued at $313,000 after buying an additional 278 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 190.9% in the first quarter. Sequoia Financial Advisors LLC now owns 23,495 shares of the medical research company’s stock valued at $1,703,000 after buying an additional 15,417 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Edwards Lifesciences by 15.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 68,013 shares of the medical research company’s stock worth $4,823,000 after purchasing an additional 8,915 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on EW. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Piper Sandler increased their target price on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. Robert W. Baird boosted their price target on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. Morgan Stanley boosted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $76.15 on Monday. The stock has a market cap of $44.70 billion, a P/E ratio of 10.96, a P/E/G ratio of 3.65 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a fifty day moving average price of $77.37 and a two-hundred day moving average price of $76.48. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.70 earnings per share. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.